Specialty Pharma Journal Specialty, Precision & Technology
SAN DIEGO, Dec. 18, 2018 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc., an innovator in predicting disease …
Tag Archives: biomarkers
December, 2018
November, 2018
-
29 November
AstraZeneca and Biocartis Enter Partnership Aimed at Faster Lung Cancer Biomarker Results
Mechelen, Belgium, 29 November 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces it has entered into an agreement with AstraZeneca, a global science-led biopharmaceutical company (LON: AZN), aimed at obtaining faster lung cancer molecular diagnostic biomarker results in Europe. …
October, 2018
-
19 October
Merrimack Discontinues Mid-Stage Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC. This decision was made in agreement with …
August, 2018
-
29 August
Genprex Amends Options to License Additional Cancer Fighting Technologies from MD Anderson Cancer Center
AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to extend the …
July, 2018
-
12 July
Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon smoking history, capturing risk for people who have ever smoked, not only for heavy smokers, an international research team reports in JAMA Oncology. “This simple blood test demonstrates the potential of biomarker-based risk assessment …
-
5 July
Discovery of New Biomarker Could Provide Personalized Treatment Options for Bladder Cancer
A potential new target for treatment has been identified in an aggressive form of bladder cancer, Mount Sinai researchers report. The cancer, called p53-like bladder cancer, is named after an active gene signature it is associated with. It is often particularly aggressive, though individual prognoses can vary quite a bit. …
June, 2018
-
7 June
Microbiotica Enters into Microbiome Collaboration with Genentech
CAMBRIDGE, England–(BUSINESS WIRE)–Microbiotica, a leading player in microbiome-based therapeutics spun out of the Wellcome Sanger Institute, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise biomarkers, targets and medicines for inflammatory bowel disease (IBD). Under …
-
1 June
Halozyme Identifies Plasma Biomarkers as Potential Predictors of Survival in Pancreatic Cancer
SAN DIEGO, June 1, 2018 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present data evaluating certain biomarkers as potential predictors of survival in patients with previously untreated metastatic pancreatic ductal adenocarcinoma at the American Society of Clinical Oncology (ASCO) annual meeting, …
May, 2018
-
3 May
Foundation Medicine Launches Gene Expression Profiling Program to Identify Known and Novel Biomarkers in Advanced Cancer
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development. This initiative, which provides a natural complement to Foundation Medicine’s comprehensive genomic profiling (CGP) suite of molecular information tests, further enhances support for the Company’s biopharma partners in …
April, 2018
-
27 April
Centogene Publishes Study Identifying the Best Biomarker for Monitoring Response to Therapy for Patients with Gaucher Disease
ROSTOCK, Germany–(BUSINESS WIRE)–CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, announced the publication of a scientific paper in the March issue of the American Journal of Hematology. Professor Ari Zimran, M.D., Gaucher unit, Shaare Zedek Medical Center, Hebrew University, Jerusalem, with additional colleagues from …